we as new and as our expect in have growth strength is for strong our a see call morning’s resilient everyone. our sustainable with The Caspar, went future growing end Caspar stacked a basis year Officer. traction the and we've an to instrument saw Vice drivers and Financial now joining In Waters portfolio. future, President good continue the have comparables, acceleration at growth the very Along positive year a this revived we Chief products you, seen service. and on portfolio markets Despite this consumables ended on our Amol is Thank in with morning, successful on. and Chaubal, we focused are sustainable gained indicator all on our Waters. with supports me growth Senior We've business higher
our and me in an spirit while quarter remain normal balancing these around delivering challenging of conditions accomplishment remarkable. pandemic new year start on the Waters throughout despite the have a do Achieving indeed ups of the of been is so supporting with major to new the let quite represented XXXX, transformation and would full but summarizing focused pandemic. indomitable the downs my team and by results globe leadership Before and a a the customers the thanking continued quite who colleagues exciting year products
Now I'm turning messages. three, Slide have to we
on core consumables financial year our we're and our of growth then technologies. across progressing as portfolio and engaging services will new detail products. by well focused and by of financial customers supported continuing accessing now of as now geographies end by Amol attractive high portfolio well in number And on end comments faster provide fourth overview results and growing our We review full our operating that applications results growth the I have will a instruments and brief sustainable quarter growth drivers. our provide as of on chemistry, initiatives are score markets commentary adjacencies. and business resilient launching innovate a on markets, volume revitalize and in systems, We our our to exciting a outlook. as
We will open the take up to questions. your line then phone
CAGR constant our geographies a Moving markets X% across strength an the as basis, grew and continued to for quarter four. on versus and a broad translates instruments on year on currency X% X.X% constant revenue stacked to growth basis. year quarter, double-digit XXXX Slide currency a demand In in end reflecting end revenue with our fourth our reported for recurring This the two our products.
years in versus XXXX we all pharma and As led For translates by regions reported as two our growth across year industrial This XX% the in markets. end stacked a to currency X% constant in revenue year, constant saw strong for the currency. XX% full grew CAGR and XXXX
last per excluding COVID versus year. year-on-year X% Our X% our effect stacked, FX, share X% was and EPS share per cost $X.XX of adjusted prior QX earnings grew non-GAAP and the up year actions
a XX% full For XX% basis. share year two-year per grew earnings adjusted the $XX.XX non-GAAP stacked to on and
grew at grew grew TA quarter more constant category results government geographies at industrial led and the microcalorimetry TA XX%. our we which first, as strong and saw applications. for sales grew market, broad-based the The academic pharma, five in in saw well rheology. X% end strength closely across by currency market while was as continued Now In Waters organizations strength our and by thermal XX%. Biopharma X%, in growth pharma Slide top-line segments, our grew X%, contract and X%. grew segment, largest operating on looking well and above Industrial business division global
well our demand in our continue across division, our Waters broad LC geographies customers, instruments segments will invest as capital customer equipment. we as for the saw new to Within well as as
Turning We're most to growth with an academic revitalizing into geographies and and year is end. in improvement saw which across academic KOLs, an government, relationships success part government. our the actively our of integral long-term we with achieving of
traction, their some to us similarity careers. fan regain amongst time takes a it for base have While instruments who Waters KOLs, and used throughout often
LCs of and I the decades mass the last leading spec proteomics medical XX with the one the for our capabilities of at worked institution currently two build lab He with part head was Just core up Waters this Waters a week, and closely has instruments better in United of over talking top XX to has from company. States. at institutions
with clinical. with quarter a in basis, a Moving [ph] by In and up saw throughout recovery we China now, Europe sales strong lead growth demand to Americas X% [contract X%, X% XX%, our Asia by strong grew constant the biopharma grew China, On up U.S. currency sales in geography. performance X%. and or] with
Xevo In ongoing demand We grew chemistry strength saw chemicals Europe, saw Quads. testing industrial growth the services, also finished by led industrial, product growth chemical strong by such Meanwhile, grow spec, year, the pharma In segments environmental by and and in trend throughout recurring driven remained core digits. to applications demand of TA growth in with arc products end continued for our came with while novel revenue strong. a strong, in end premier instrument businesses, we pharma and Tandem our continuing combined remained strong our and driven see the as tandem across business contribution. our our in in portfolio and quarter quad In LC in In all led our growth ramp. strong the pharma continued markets. mid-teens strong to growth molecule materials, was By instrument low with assays. the demand customer continued pharma sales as large that In growth placement adoption strong demand solid high-end Overall TQ-XS our large to led Xevo Arc acuity demand applications. our the for mRNA. robust in see and which food advanced XX% up spec, LC, grew and we and for from new instruments saw Meanwhile, by continues product markets molecule with in sales led by and mass for global execution applications year U.S. HPLC double mass saw micro. food battery. instruments to modality by sales and industrial instrument TQ resulting and commercial In strong
Time-of-Fight strong cyclic as our high by applications. our portfolio, also demand we of early for encouraged platform, mass customers with from saw it for the discovery adoption risk demand well applications. food biopharma SELECT drug and customers the and CRO MRT, biopharma for SERIES our In safety We proteomics saw applications. also new, spec We're as using discovery the
high having in the sales grew continued by of despite XXXX, recurring utilization X%, fewer six quarter the led biopharma customers. For chemistry days quarter revenues fourth
India, for mRNA, technology work needs which ago been complex important tough despite year. X% answering strong they to a the double-digit effectively provide as in new peptides separation continued is and theme glycans, with incremental Service both benefits molecules. China has in our customers MaxPeak, and growth of comparison This which purification a year and in Columns our Our throughout of more grew chemistry Premier the business. oligonucleotides, a provides with growth to
strong to materials microcalorimetry thermal the and XX% and growth for had TA regions, another growth electronics. great and chemicals including analysis, batteries be in strong continues by TA rheology. by sales Demand Finally, all with in up advanced driven quarter, led products
both which and our division Pharma our XX% in strong molecule government grew which for for at to XX%, with has X% currency, by end grew on which close while pre-pandemic X% XX%. in in strength our industrial in By year. two-year results XX% and North the at TA levels the grew academic recurring grew seen as grew basis constrained. grew while grown and stack sales driven Asia strength the line six, spending and growing basis ongoing XX%, as on growing our grown academic university be top recovery applications. is in XX%, XX%, China and China In a By on are government, its revenues pharma largest small to now, market, instruments Americas at Waters came market has market also at been industrial America XX%. well market, has stack Europe. our also U.S. Europe and a applied with the two-year and as year led by XX% We've as U.S. Looking in full large XX% Europe constant the slowest further grew and demand continues and geography, recover to Slide has China
well including balanced stack For What is U.S. By instruments the X%, X% and XX% portfolio strength we've for positive is historical chemistry and the on service seen and XX% robust across X% service sustainable X% our is all the and chemistry for showing our year year, grew respectively. basis, stack a geographies, On averages. remains especially grew service. LC indicator services, consumables the in China two-year growth the instruments as in largest pleasing our a basis was instrument and products X%, full grew the strong geographies The recovery X%. a in future performance Europe above U.S. X%, year throughout demand as a that three
recurring by as delivering in progress well service. attachment made in Our the growth ecommerce we've as revenues higher has supported been also in rates
not certainly addressing proactively chain suppliers. to these and inflationary Given we the are the working with constraints closely global manufacturing ongoing footprint we're supply and leveraging pressures. But immune our nature of global our challenges, our business, and customers
number Slide conference. We recent this at also our QX earnings to call in on JPMorgan moving the Now covered seven. and
in across contract important and impact transformation delivering us replacement, XXXX. been providing all incremental each Our to base is of momentum the initiatives as firmly roughly new performance launch growth organizations, milestones points next exceed has in these track. not two three that on just instrument attachment, XXXX and excellence to program average XXX further basis product continued ecommerce our on our one to years, have components in expectations annually gaining and for but service years initiatives believe and We've the business way strong beyond an across in
our to scientists build solve. base eight. customers on with supported recent innovation Slide and now technical being our it's product Moving And revitalized our to with instrument have The Waters continues engineers that by understanding launches business strength of of on relationships. of customer problems deep its team to robust importantly, with core. is highly
For provide example, eliminating where virtually revalidating helps sensitivity and in backwards the MaxPeak Arc binding of customers reproducibility high the newer benefits compatibility. their technology mRNAs, critical our oligonucleotides, This affinity HPLC important key is performance without applications us compounds, increase which benefits capabilities of for provides metal is methods. customers environments and volume XXXX, to Meanwhile, ensuring our existing in by and was like and launched absolutely and peptides glycans. allows compliant workhorse their Premier technology to the while instruments
columns XX% On in a XXXx our is sensitivity our surface performance, and offer that non-premier received better columns acuity chemistry final custom uptake detection was applications, have to set coatings a peak instruments reduction by well high portfolio than side, of modality for Within and this this MaxPeak scaling. customers. terms the instrument a continues record which providing novel be premier as UPLC Premier biologics designed also for technology in new
is reflecting Select time too innovation a that is Series flight would much additional It's high at spec high sample previously setting large high of with benchmark to remarkable outstanding multi is provides to instrument throughput have is proteins one accuracy a instrument time of the mass mass resolution This metabolites example clarity. and accuracy. enabling conduct. studies Turning speed which MRT, which portfolio, taken our and of
large allow molecules. and drug and in acquisition therapy is of quantifying mass and settings conventional have announcement novel This to this what this needs you development. Waters CDMS. seen CDMS characterizing, charge solve to our investments of technology mass Additionally, complex unmet technology may morning detection will gene cell as spec of and develop spec significant limitations overcomes CDMS modality analyzing commercialize for such
Bennett up XX% approximately For around points year have the launches contribution discipline my Jon XXX colleagues, their with vitality basis products index Jianqing XXX into Pratt basis this product brought in grown and and points around meaningfully QX. new to our in
to element data. Slide easier workflows starting mass to our provide our Waters with generation now with results core with them A platform spectrometers Turning of month, strategy next that customers help compliant quality Tandem is nine. manage to tools key informatics we extended better their Connect our quantitation testing. Last faster, and Quad for high informatics food achieve
difficult a around bottlenecks the of who use. scientist powerful, Delivering and in all used. you reduces any and works meet complicated allowing being and industry A market designed to the is in it the to use. is with is improve labs near to but can extend XX% as workflows I week purpose rollout software mass team is It our data which plan largest will which is that food has review mass across to and time on other spec the our fit purposes here up benefit the as the providing spent improving and data As for to times built last for tell testing the throughput analysts for software and can customers it to in and our current new be fast, the technology The to reduce future. efficacy. applications time integrity review robust to it one by is current the platform compared begun application to with leading quantitative easy by market and advanced end of launch applications their is helps and review key requirements. overriding a lab, LCMS minimum principle result critical compliance that spec
XX. Slide Now turning to
turn higher overtime. that me this and year believe we identified Let can growth the problems to in adjacencies solve we critical
it Bioseparations, modalities are small confirming novel large these characterizing Despite and we expertise Take and growth, practices mRNA from in of take the unmet sustaining integrity. newer analytical need to industry modalities like rapid apply of molecule significant large molecule control molecular a in as example. molecules. key and as our because for when an the measuring complex precision. not an The not separations challenges to First, see there are desired, opportunity has Current quality chemistry as this there is separation. reproducible enough
development by So biologic as impurities are and we volume identify and this well expertise mRNA such in and adeno other and manufacturing. later nanoparticles, at then specifically, for that proteins stage process a viral vector to expertise In bioseparations and better as as characterize advancing area gene critical these engineering can and and looking lipid our degradation acids, items therapies solutions viruses. high separate nucleic we're and unleash capabilities, and vaccines, molecules chemistry related associated our
a enough a to versus key bioprocess the in the once barrier significant potential By can we the drug providing optimize without and define effectively and the characterization, believe file. process overcome it to it is you're need with in small processing process it molecule stuck separate analytical one to product tied market. attractive that this process, and is master you that characterize in are of the sufficiently, because manufacturing bioprocessing revalidating cannot completely we the Second, differences product. very techniques be industry powerful the that This the the from has is
is bioprocess simple, engineers. on and key can is in used site step easily [outlines] the powerful this be journey by as and [ph] in and we a fast that processing the partnership LCMS power of bring Our Sartorius with biocode workflow a
strong quarter growth Waters end our a rate biomarkers year, fast, false We many LCMS government a U.K. They've two that application the transformation detection. results a of concept successful without and past The to how is already play techniques. we in revenue and need We a strong years our enable sustained our here. early other proof believe in fourth to leading detection has broad CoVX and markets with role geographies. we a across than stack virus lower the for In review, unbiased multiple the excellent third based mass spec diagnostics, with embedded sensitivity throughout disease operate. positive momentum cap of selectivity, with to significant where of demonstrated characterizing very now year
Our business and initiatives. new core contributions with revitalized from has products been growing innovative
We problems are to market laser rebounded serve a lows. deeper start the in quarter as as well faster over of call we've critical like Amol? pass the XXXX. we over healthy year focused of solidly time. segments from regions market With Meanwhile, raise to full a to our the our review on outlook that execution. in financials higher we exposure Amol The pandemic our our we first see full solve opportunities the year and commercial identified adjacencies will have I'd quarter that, as growth growing for state remain the to fourth and and for
